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unmedicated, ADHD in adults has a negative impact on labor force participation in 
the US. Irrespective of whether or not the ADHD is medicated, its presence also has 
a signiﬁcant impact on increased absenteeism and presenteeism.
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OBJECTIVES: To examine psychiatric-related health care costs and inpatient utiliza-
tion among patients with type I bipolar disorder who relapse frequently within a large 
Medicaid database. METHODS: A large multistate Medicaid claims database (Mar-
ketScan®) was used to identify patients aged 18 to 64 years with type I bipolar disor-
der; ≥1 prescription claim for lithium, an anticonvulsant, or an antipsychotic between 
January 1, 2004 and December 31, 2005; and ≥24 months’ continuous enrollment. 
Frequent relapse (FR) was deﬁned as ≥2 clinically signiﬁcant events (CSEs) occurring 
during a 12-month identiﬁcation period beginning with the initial CSE (if any). CSEs 
included emergency room (ER) visits or inpatient hospitalizations (IH) with a principal 
diagnosis of bipolar disorder or a change in bipolar disorder medication(s). Patients 
were followed for a subsequent 12-month period to evaluate health care utilization 
and associated costs. Generalized linear modeling was used to estimate the impact of 
FR on psychiatric-related health care costs; logistic regression was used to estimate 
the impact of FR on psychiatric IH and ER visits. RESULTS: Of 5527 patients with 
type I bipolar disorder, 53% relapsed frequently. Of the patients with FR, 75% were 
female. Close to one-third (29%) of patients who relapsed frequently in the identiﬁca-
tion period also relapsed frequently in the follow-up period. During the 12-month 
follow-up period, patients with FR had higher adjusted per-patient psychiatric-related 
health care costs (mean $6014 vs $3495; P < 0.001), 3.7 times greater odds of psy-
chiatric IH (P < 0.01), and 3.1 times greater odds of psychiatric-related ER visits (P 
< 0.01) than patients who did not relapse frequently. CONCLUSIONS: Medicaid 
patients with type I bipolar disorder who relapsed frequently had signiﬁcantly higher 
adjusted psychiatric-related health care costs and greater odds of IH and ER events 
in a subsequent period than patients who did not relapse frequently. Supported by 
funding from Ortho-McNeil Janssen Scientiﬁc Affairs, LLC.
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OBJECTIVES: To estimate the rates and costs of all-cause and psychiatric-related 
hospitalizations and ER visits among patients with bipolar I disorder. METHODS: 
Retrospective cohort analysis of multistate Medicaid patients who were aged ≥18 
years, had ≥1 inpatient or ≥2 outpatient medical claims indicating bipolar I disorder 
(ICD-9-CM codes 296.0X-296.1X, 296.4X-296.7X), and ﬁlled ≥1 prescription for an 
antipsychotic medication between January 1, 2004, and December 31, 2006. Patients 
were followed for 1 year from the date of ﬁrst, or index, antipsychotic prescription. 
Patients were required to be continuously eligible for Medicaid without dual Medicare 
eligibility from 1 year before (baseline) through 1 year after (follow-up) index, and 
were required to receive ≥1 additional antipsychotic claim during follow-up to ensure 
a treated population. Descriptive statistics were generated on the use and costs 
(proxied by Medicaid payments) of hospitalizations and ER visits, both all-cause and 
psychiatric-related (ICD-9-CM 290.XX-319.XX). RESULTS: 9410 patients met study 
eligibility criteria. Mean (±SD) patient age was 38.0 (±11.9) years, 74% were female, 
and 75% were white. Approximately 31% and 57% had preexisting diagnoses of 
substance abuse and psychiatric conditions, respectively. During follow-up, 40% of 
patients were hospitalized for any reason (37% with a psychiatric diagnosis). Patients 
had an average (±SD) of 0.9 (±1.7) all-cause and 0.8 (±1.6) psychiatric-related hospi-
talizations. All-cause and psychiatric-related ER visits occurred in 67% and 29% of 
patients, with an average (±SD) of 6.1 (±10.9) and 0.9 (±2.7) visits per patient, 
respectively. Average (±SD) costs were $6986 (±$10,374) and $6916 (±$10,288) for 
all-cause and psychiatric-related hospitalizations, and $158 (±$218) and $256 (±$416) 
for all-cause and psychiatric-related ER visits, respectively. CONCLUSIONS: Hospi-
talizations, ER visits, and costs were substantial among patients with bipolar I disor-
der. Studies investigating predictors of hospitalizations and ER visits in this patient 
population are warranted. Supported by funding from Ortho-McNeil Janssen Scien-
tiﬁc Affairs, LLC.
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OBJECTIVES: It is important for the management of a psychiatric hospital having an 
acute-care ward to estimate medical practice revenues under different conditions. We 
developed a system dynamics (SD) simulation model for the treatment of acute schizo-
phrenia to investigate the effect of the treatment of patients with acute schizophrenia 
on the hospital management. METHODS: We developed an SD simulation model for 
patient admission and discharge at a psychiatric acute-care ward. The model assumed 
an imaginary, newly built psychiatric hospital consisting of 3 types of wards: a psy-
chiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care 
ward. The rates of discharge were set at 40%/month, 30%/month and 20%/month 
for a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric 
nursing-care ward, respectively. The number of newly admitted patients was supposed 
to be 10 per month. We compared the total medical practice revenues at 36 months. 
RESULTS: Up to 9 months of outpatient treatment, the total medical practice revenues 
increased and then decreased at 12 months. A 2-way sensitivity analysis on the ﬁrst-
time admissions and the duration of outpatient treatment revealed that the total 
medical practice revenues were higher when the number of newly admitted patients 
was 5–11 at 9 months of outpatient management; however, when the number of newly 
admitted patients was 12–15, the maximum medical practice revenue was obtained 
at 12 months of outpatient management. CONCLUSIONS: Total medical practice 
revenues change depending on the rates of discharge from a psychiatric acute-care 
ward, the duration of outpatient treatment and the number of newly admitted patients. 
A budget plan for each psychiatric hospital having a psychiatric acute-care ward 
should be based on the calculation of those parameters and a systematic approach to 
patient management is important.
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OBJECTIVES: ADHD medication users frequently take ‘drug holidays’ during the 
summer months. The study objective was to compare ADHD medication adherence 
for an entire year (EY-365 days) and the school year (SY-270 days) by medication 
class and type. METHODS: Continuously enrolled Texas Medicaid children (≤18 
years) who had ≥2 prescription claims for an ADHD medication served as the study 
population. EY and SY (September 1-May 31) prescription claims were extracted from 
July 2002-December 2008. Prescription claims were grouped by medication class 
[immediate release(IR), extended release(ER), long-acting(LA), non-stimulant(NS)]; 
and medication type [stimulant(S) vs. non-stimulant(NS)]. Adherence, assessed by 
medication possession ratio (MPR) using a ﬁxed interval denominator, was measured 
both continuously and dichotomously (80%). T-tests, ANOVAs and chi-square were 
employed to determine differences between groups. RESULTS: Overall mean adher-
ence for EY (n = 62,789) was 49.8 ± 30.3 and SY (n = 50,842) was 62.2 ± 26.2. For 
EY, mean medication class adherence was not signiﬁcantly different between NS (52.5 
± 30.9) and ER (52.1 ± 30.2); however, LA (47.6 ± 30.9) and IR (37.2 ± 27.1) were 
signiﬁcantly lower (p < 0.0001). Regarding SY, adherence was not signiﬁcantly dif-
ferent among ER (63.7 ± 26.0), LA (63.5 ± 23.8) and NS (62.9 ± 27.0), while IR (52.8 
± 24.7) was signiﬁcantly lower (p < 0.0001). When adherence was dichotomized, EY 
medication class adherence differed signiﬁcantly (p < 0.0001): NS(25.8%), ER(24.1%), 
LA(21.2%), IM(9.8%). Similarly, SY differed signiﬁcantly (p < 0.0001): NS(30.8%), 
ER(30.0%), LA(25.6%), IM(16.2%). NS had signiﬁcantly higher mean adherence 
than S, respectively: EY(52.5 ± 30.9 vs. 49.4 ± 30.2; p < .0001) and SY(62.9 ± 27.0 
vs. 62.1 ± 26.1; p < .01). When dichotomized, results were similar (p < .0001): 
EY(25.8% vs. 21.5%) and SY(30.8% vs. 27.9%). CONCLUSIONS: Subjects were 
more adherent during SY compared to EY. Medication class mean adherence differed 
depending on timeframe used. For analyses comparing NS and S, NS had signiﬁcantly 
higher adherence, however for SY mean adherence, the difference may not be practi-
cally signiﬁcant. Due to unique patient medication-taking behaviors, ADHD medica-
tion adherence differs depending on the timeframe used.
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OBJECTIVES: Adherence and persistence with prescribed medication is important in 
the treatment of major depressive disorder (MDD). This study compared adherence 
and persistence of 3 branded antidepressants (duloxetine, venlafaxineXR, and esci-
talopram) and generic selective serotonin reuptake inhibitors (SSRIs) in the real-world 
treatment of MDD. METHODS: A total of 44,026 MDD patients (18 to 64 years) 
